In CRC, the TP53 gene is frequently mutated, with approximately 43–50% of tumors harboring missense mutations that not only impair the tumor-suppressing functions of wild-type p53 but also confer gain-of-function activities that promote cancer progression, stemness, and metastasis [146,147]. This evidence concerns the gene TP53 and cancer.